Curative therapies for hepatocellular carcinoma: an update and perspectives

References

• Cabibbo G, Maida M, Genco C, et al. Causes of and prevention strategies for hepatocellular carcinoma. Semin Oncol. 2012;39:374–383.
   PubMed Web of Science ®Google Scholar
• Cammà C, Cabibbo G. Prognostic scores for hepatocellular carcinoma: none is the winner. Liver Int. 2009;29:478–480.
   PubMed Web of Science ®Google Scholar
• Akoad ME, Pomfret EA. Surgical resection and liver transplantation for hepatocellular carcinoma. Clin Liver Dis. 2015;19:381–399.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
   PubMed Web of Science ®Google Scholar
• Munene G, Vauthey JN, Dixon E. Summary of the 2010 AHPBA/SSO/SSAT Consensus Conference on HCC. Int J Hepatol. 2011;2011:565060.
   PubMedGoogle Scholar
• Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol. 2015;7:673–687.
   PubMed Web of Science ®Google Scholar
• Lee KK, Kim DG, Moon IS, et al. Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. J Surg Oncol. 2010;101:47–53.
   PubMed Web of Science ®Google Scholar
• Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134:1908–1916.
   PubMed Web of Science ®Google Scholar
• Cucchetti A, Ercolani G, Vivarelli M, et al. Is portal hypertension a contraindication to hepatic resection? Ann Surg. 2008;250:922–928.
   Web of Science ®Google Scholar
• Schlachterman A, Craft WW Jr, Hilgenfeldt E, et al. Current and future treatments for hepatocellular carcinoma. World J Gastroenterol. 2015;21:8478–8491.
   PubMed Web of Science ®Google Scholar
• Kinoshita H, Sakai K, Hirohashi K, et al. Preoperative portal vein embolization for hepatocellular carcinoma. World J Surg. 1986;10:803–808.
   PubMed Web of Science ®Google Scholar
• Li N, Wu YR, Wu B, et al. Surgical and oncologic outcomes following laparoscopic versus open liver resection for hepatocellular carcinoma: A meta-analysis. Hepatol Res. 2012;42:51–59.
   PubMed Web of Science ®Google Scholar
• Morise Z, Kawabe N, Tomishige H, et al. Recent advances in liver resection for hepatocellular carcinoma. Front Surg. 2014;1:21.
   PubMedGoogle Scholar
• Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer .2 cm: results from two Western centers. Hepatology. 2013;57:1426–1435.
   PubMed Web of Science ®Google Scholar
• Nault JC, De Reyniès A, Villanueva A, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology. 2013;145:176–177.
   PubMed Web of Science ®Google Scholar
• Minagawa M, Makuuchi M, Takayama T, et al. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg. 2003;238:703–710.
   PubMed Web of Science ®Google Scholar
• Yang T, Lin C, Zhai J, et al. Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging. J Cancer Res Clin. 2012;138:1121–1129.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Chun YS, Poon RT, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008;15:1001–1007.
   PubMed Web of Science ®Google Scholar
• De Lope CR, Tremosini S, Forner A, et al. Management of HCC. J Hepatol. 2012;56(Suppl 1):S75–87.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Bhoori S, Sposito C, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011;17(Suppl 2):S44–57.
   PubMed Web of Science ®Google Scholar
• Guglielmi A, Ruzzenente A, Conci S, et al. Hepatocellular carcinoma: surgical perspectives beyond the Barcelona clinic liver cancer recommendations. World J Gastroenterol. 2014;20:7525–7533.
   PubMed Web of Science ®Google Scholar
• Grant RC, Sandhu L, Dixon PR, et al. Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis. Clin Transplant. 2013;27:140–147.
   PubMed Web of Science ®Google Scholar
• Liang W, Wu L, Ling X, et al. Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl. 2012 Oct;18(10):1226–1236.
   PubMed Web of Science ®Google Scholar
• Schwartz M, Dvorchik I, Roayaie S, et al. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J Hepatol. 2009;49:581–588.
   Web of Science ®Google Scholar
• Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–994.
   PubMed Web of Science ®Google Scholar
• Toso C, Asthana S, Bigam DL, et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology. 2009;49:832–838.
   PubMed Web of Science ®Google Scholar
• Sacco R, Gadaleta-Caldarola G, Galati G, et al. EASL HCC summit: liver cancer management. Future Oncol. 2014;10:1129–1132.
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Maida M, Genco C, et al. Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. PLoS One. 2013;8:e70016.
   PubMed Web of Science ®Google Scholar
• Latteri F, Sandonato L, Di Marco V, et al. Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. Dig Liver Dis. 2008;40:684–689.
   PubMedGoogle Scholar
• Kim YS, Lim HK, Rhim H, et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58:89–97.
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Antonucci M, Sacco R, et al. Ultrasound-guided ablation for hepatocellular carcinoma: time for a reappraisal? Exp Rev Anticancer Ther. 2015;15:147–150.
   PubMed Web of Science ®Google Scholar
• Germani G, Pleguezuelo M, Gurusamy K, et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocellular carcinoma: a meta-analysis. J Hepatol. 2013;52:380–388.
   Google Scholar
• Oeda S, Mizuta T, Isoda H, et al. Survival advantage of radiofrequency ablation for hepatocellular carcinoma: comparison with ethanol injection. Hepatogastroenterology. 2013;60:1399–1404.
   PubMed Web of Science ®Google Scholar
• Shen A, Zhang H, Tang C, et al. Systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm. J Gastroenterol Hepatol. 2013;28:793–800.
   PubMed Web of Science ®Google Scholar
• Giorgio A, Di Sarno A, De Stefano G, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res. 2011;31:2291–2295.
   PubMed Web of Science ®Google Scholar
• Cucchetti A, Piscaglia F, Cescon M, et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol. 2013;59:300–307.
   PubMed Web of Science ®Google Scholar
• Yang B, Zan RY, Wang SY, et al. Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. World J Surg Oncol. 2015;13:96.
   PubMed Web of Science ®Google Scholar
• Forner A, Bruix J. Ablation for hepatocellular carcinoma: is there need to have a winning technique? J Hepatol. 2010;52:310–312.
   PubMed Web of Science ®Google Scholar
• Fu C, Liu N, Deng Q, et al. Radiofrequency ablation vs. surgical resection on the treatment of patients with small hepatocellular carcinoma: a system review and meta-analysis of five randomized controlled trials. Hepatogastroenterology. 2014;61:1722–1729.
   PubMed Web of Science ®Google Scholar
• Huang J, Yan L, Wu H, et al. Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation? J Surg Res. 2015. [ Epub ahead of print].
   Web of Science ®Google Scholar
• Lei JY, Wang WT, Yan LN, et al. Radiofrequency ablation versus surgical resection for small unifocal hepatocellular carcinomas. Medicine (Baltimore). 2014;93:e271.
   PubMed Web of Science ®Google Scholar
• Kim JM, Kang TW, Kwon CH, et al. Single hepatocellular carcinoma ≤3 cm in left lateral segment: liver resection or radiofrequency ablation? World J Gastroenterol. 2014;20:4059–4065.
   PubMed Web of Science ®Google Scholar
• Gory I, Fink M, Bell S, et al. Melbourne Liver Group. Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study. Scand J Gastroenterol. 2015;50:567–576.
   PubMed Web of Science ®Google Scholar
• Spolverato G, Vitale A, Ejaz A, et al. The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. World J Surg. 2015;39:1474–1484.
   PubMed Web of Science ®Google Scholar
• Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013;31:426–432.
   PubMed Web of Science ®Google Scholar
• Thandassery RB, Goenka U, Goenka MK. Role of local ablative therapy for hepatocellular carcinoma. J Clin Exp Hepatol. 2014;4(Suppl 3):S104–111.
   PubMedGoogle Scholar
• Attwa MH, El-Etreby SA. Guide for diagnosis and treatment of hepatocellular carcinoma. World J Hepatol. 2015;7:1632–1651.
   PubMed Web of Science ®Google Scholar
• Wang C, Wang H, Yang W, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. 2015;61:1579–1590.
   PubMed Web of Science ®Google Scholar
• Poon RT, Fan ST, Tsang FH, et al. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon’s perspective. Ann Surg. 2002;235:466–486.
   PubMed Web of Science ®Google Scholar
• Zhu H, Zhou K, Zhang L, et al. High intensity focused ultrasound (HIFU) therapy for local treatment of hepatocellular carcinoma: role of partial rib resection. Eur J Radiol. 2009;72:160–166.
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Moriyasu F, Kobayashi Y, et al. Irreversible electroporation for nonthermal tumor ablation in patients with hepatocellular carcinoma: initial clinical experience in Japan. Jpn J Radiol. 2015;33:424–432.
   PubMed Web of Science ®Google Scholar
• Niessen C, Igl J, Pregler B, et al. Factors associated with short-term local recurrence of liver cancer after percutaneous ablation using irreversible electroporation: a prospective single-center study. J Vasc Interv Radiol. 2015;26:694–702.
   PubMed Web of Science ®Google Scholar
• Cheung W, Kavnoudias H, Roberts S, et al. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. Technol Cancer Res Treat. 2013;12:233–241.
   PubMed Web of Science ®Google Scholar
• Mazzola A, Costantino A, Petta S, et al. Recurrence of hepatocellular carcinoma after liver transplantation: an update. Future Oncol. 2015;11:2923–2936.
   PubMed Web of Science ®Google Scholar
• Sacco R, Gadaleta-Caldarola G, Galati G, et al. European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: old questions, new (or few) answers? Future Oncol. 2014;10:1719–1721.
   PubMed Web of Science ®Google Scholar
• Korean Liver Cancer Study Group (KLCSG); National Cancer Center, Korea (NCC). 2014 KLCSG-NCC Korea practice guideline for the management of hepatocellular carcinoma. Gut Liver. 2015;9:267–317.
   PubMed Web of Science ®Google Scholar
• Cillo U, Burra P, Mazzaferro V, et al. I-BELT (Italian board of experts in the field of liver transplantation). A multistep, consensus-based approach to organ allocation in liver transplantation: toward a “Blended Principle Model”. Am J Transplant. 2015;15:2552–2561.
   PubMed Web of Science ®Google Scholar
• Bruix J, Takayama T, Mazzaferro V, et al. STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344–1354.
   PubMed Web of Science ®Google Scholar
• Xu J, Li J, Chen J, et al. Effect of adjuvant interferon therapy on hepatitis b/c virus-related hepatocellular carcinoma after curative therapy: meta-analysis. Adv Clin Exp Med. 2015;24:331–340.
   PubMed Web of Science ®Google Scholar
• Ishikawa T. Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol. 2013;19:8861–8866.
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51:1274–1283.
   PubMed Web of Science ®Google Scholar
• Villa E, Critelli R, Lei B, et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut. 2015. [ Epub ahead of print].
   PubMed Web of Science ®Google Scholar